Matches in SemOpenAlex for { <https://semopenalex.org/work/W2151592384> ?p ?o ?g. }
- W2151592384 endingPage "725" @default.
- W2151592384 startingPage "717" @default.
- W2151592384 abstract "Abstract There have been significant advances in the treatment of malignant melanoma with the U.S. Food and Drug Administration approval of two drugs in 2011, the first drugs approved in 13 years. The developments of immune checkpoint modulation via cytotoxic T-lymphocyte antigen-4 blockade, with ipilimumab, and targeting of BRAFV600, with vemurafenib or dabrafenib, as well as MEK, with trametinib, have been paradigm changing both for melanoma clinical practice and for oncology therapeutic development. These advancements, however, reveal new clinical questions regarding combinations and optimal sequencing of these agents in patients with BRAF mutant disease. We review the development of these agents, putative biomarkers, and resistance mechanisms relevant to their use, and possibilities for sequencing and combining these agents." @default.
- W2151592384 created "2016-06-24" @default.
- W2151592384 creator A5063337705 @default.
- W2151592384 creator A5084967339 @default.
- W2151592384 date "2013-05-24" @default.
- W2151592384 modified "2023-09-25" @default.
- W2151592384 title "Ipilimumab, Vemurafenib, Dabrafenib, and Trametinib: Synergistic Competitors in the Clinical Management of BRAF Mutant Malignant Melanoma" @default.
- W2151592384 cites W1967084952 @default.
- W2151592384 cites W1971947883 @default.
- W2151592384 cites W1982972087 @default.
- W2151592384 cites W1988379285 @default.
- W2151592384 cites W1989121777 @default.
- W2151592384 cites W1999025555 @default.
- W2151592384 cites W1999439172 @default.
- W2151592384 cites W2002937040 @default.
- W2151592384 cites W2004295816 @default.
- W2151592384 cites W2014545440 @default.
- W2151592384 cites W2017187984 @default.
- W2151592384 cites W2030578708 @default.
- W2151592384 cites W2032211985 @default.
- W2151592384 cites W2033457081 @default.
- W2151592384 cites W2038914273 @default.
- W2151592384 cites W2043058822 @default.
- W2151592384 cites W2051165598 @default.
- W2151592384 cites W2053473615 @default.
- W2151592384 cites W2055624262 @default.
- W2151592384 cites W2058390096 @default.
- W2151592384 cites W2068834940 @default.
- W2151592384 cites W2073363047 @default.
- W2151592384 cites W2091100650 @default.
- W2151592384 cites W2092606584 @default.
- W2151592384 cites W2092703991 @default.
- W2151592384 cites W2094366129 @default.
- W2151592384 cites W2095826876 @default.
- W2151592384 cites W2097995306 @default.
- W2151592384 cites W2100158834 @default.
- W2151592384 cites W2100738068 @default.
- W2151592384 cites W2102031533 @default.
- W2151592384 cites W2103220202 @default.
- W2151592384 cites W2103675014 @default.
- W2151592384 cites W2103845135 @default.
- W2151592384 cites W2105017308 @default.
- W2151592384 cites W2106494998 @default.
- W2151592384 cites W2106543129 @default.
- W2151592384 cites W2108789863 @default.
- W2151592384 cites W2109465910 @default.
- W2151592384 cites W2112552042 @default.
- W2151592384 cites W2116376943 @default.
- W2151592384 cites W2119198740 @default.
- W2151592384 cites W2123363005 @default.
- W2151592384 cites W2124196948 @default.
- W2151592384 cites W2125485324 @default.
- W2151592384 cites W2128208856 @default.
- W2151592384 cites W2128542677 @default.
- W2151592384 cites W2134638467 @default.
- W2151592384 cites W2136474966 @default.
- W2151592384 cites W2138134458 @default.
- W2151592384 cites W2141674733 @default.
- W2151592384 cites W2141756397 @default.
- W2151592384 cites W2143467222 @default.
- W2151592384 cites W2144096834 @default.
- W2151592384 cites W2148586726 @default.
- W2151592384 cites W2149244682 @default.
- W2151592384 cites W2149662085 @default.
- W2151592384 cites W2151507811 @default.
- W2151592384 cites W2154196978 @default.
- W2151592384 cites W2155461614 @default.
- W2151592384 cites W2156078931 @default.
- W2151592384 cites W2164918836 @default.
- W2151592384 cites W2166262263 @default.
- W2151592384 cites W2166626276 @default.
- W2151592384 cites W2168143310 @default.
- W2151592384 cites W2172131454 @default.
- W2151592384 cites W4241343949 @default.
- W2151592384 doi "https://doi.org/10.1634/theoncologist.2012-0391" @default.
- W2151592384 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4063399" @default.
- W2151592384 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23709751" @default.
- W2151592384 hasPublicationYear "2013" @default.
- W2151592384 type Work @default.
- W2151592384 sameAs 2151592384 @default.
- W2151592384 citedByCount "70" @default.
- W2151592384 countsByYear W21515923842013 @default.
- W2151592384 countsByYear W21515923842014 @default.
- W2151592384 countsByYear W21515923842015 @default.
- W2151592384 countsByYear W21515923842016 @default.
- W2151592384 countsByYear W21515923842017 @default.
- W2151592384 countsByYear W21515923842018 @default.
- W2151592384 countsByYear W21515923842019 @default.
- W2151592384 countsByYear W21515923842020 @default.
- W2151592384 countsByYear W21515923842021 @default.
- W2151592384 countsByYear W21515923842022 @default.
- W2151592384 countsByYear W21515923842023 @default.
- W2151592384 crossrefType "journal-article" @default.
- W2151592384 hasAuthorship W2151592384A5063337705 @default.
- W2151592384 hasAuthorship W2151592384A5084967339 @default.
- W2151592384 hasBestOaLocation W21515923841 @default.
- W2151592384 hasConcept C126322002 @default.
- W2151592384 hasConcept C143998085 @default.